Selection of molecular targets based on disease understanding is a dominant paradigm in drug discovery. We argue that a focus on classes of targets with central roles in biology provides a complementary approach that has higher quality outcomes in early discovery efforts.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Prinz, F., Schlange, T. & Asadullah, K. Nat. Rev. Drug Discov. 10, 712 (2011).
James, L.I. & Frye, S.V. Curr. Opin. Chem. Biol. 33, 135–141 (2016).
Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K. & Schapira, M. Nat. Rev. Drug Discov. 11, 384–400 (2012).
Ting, A.H., McGarvey, K.M. & Baylin, S.B. Genes Dev. 20, 3215–3231 (2006).
Filippakopoulos, P. & Knapp, S. Nat. Rev. Drug Discov. 13, 337–356 (2014).
Kettle, J.G. & Wilson, D.M. Drug Discov. Today 21, 1596–1608 (2016).
Heilker, R., Wolff, M., Tautermann, C.S. & Bieler, M. Drug Discov. Today 14, 231–240 (2009).
Willson, T.M. & Moore, J.T. Mol. Endocrinol. 16, 1135–1144 (2002).
Bagal, S.K. et al. J. Med. Chem. 56, 593–624 (2013).
Lane, S.J. et al. Drug Discov. Today 11, 267–272 (2006).
Herold, J.M., Ingerman, L.A., Gao, C. & Frye, S.V. Curr. Chem. Genomics 5, 51–61 (2011).
Müller, S., Chaikuad, A., Gray, N.S. & Knapp, S. Nat. Chem. Biol. 11, 818–821 (2015).
Wu, P., Nielsen, T.E. & Clausen, M.H. Drug Discov. Today 21, 5–10 (2016).
Frye, S.V. Chem. Biol. 6, R3–R7 (1999).
Patricelli, M.P. et al. Chem. Biol. 18, 699–710 (2011).
Simon, G.M., Niphakis, M.J. & Cravatt, B.F. Nat. Chem. Biol. 9, 200–205 (2013).
Weiss, W.A., Taylor, S.S. & Shokat, K.M. Nat. Chem. Biol. 3, 739–744 (2007).
Roth, B.L. & Kroeze, W.K. J. Biol. Chem. 290, 19471–19477 (2015).
Urban, J.D. et al. J. Pharmacol. Exp. Ther. 320, 1–13 (2007).
Kim, J. et al. EMBO Rep. 7, 397–403 (2006).
Bollag, G. et al. Nat. Rev. Drug Discov. 11, 873–886 (2012).
Frye, S.V. et al. Nat. Rev. Drug Discov. 14, 733–734 (2015).
Barnash, K.D. et al. ACS Chem. Biol. 11, 2475–2483 (2016).
Weerapana, E. et al. Nature 468, 790–795 (2010).
Martinez Molina, D. et al. Science 341, 84–87 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Barnash, K., James, L. & Frye, S. Target class drug discovery. Nat Chem Biol 13, 1053–1056 (2017). https://doi.org/10.1038/nchembio.2473
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2473
This article is cited by
-
RNA-modifying proteins as anticancer drug targets
Nature Reviews Drug Discovery (2018)